by The global Circulating Tumor Cells market size is expected to be worth around US$ 20.3 billion by 2030, according to a new report by Vision Research Reports.
Circulating Tumor Cells Market (By Technology: CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis; By Application: Clinical/ Liquid Biopsy, Research; By Product: Kits & Reagents, Blood Collection Tubes, Devices or Systems; By Specimen: Blood, Bone Marrow, Other Body Fluids) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030
Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/38319
Market Insight
| Report Coverage | Details |
| Market Size | US$ 20.3 billion by 2030 |
| Growth Rate | CAGR of 15.7% From 2021 to 2030 |
| Base year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Technology, Application, Product, Specimen |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | QIAGEN; Bio-Techne Corporation; Precision for Medicine; AVIVA Biosciences; BIOCEPT, Inc.; BioCEP Ltd.; Fluxion Biosciences, Inc.; Greiner Bio One International GmbH; Ikonisys Inc.; Miltenyi Biotec; IVDiagnostics; BioFluidica; Canopus Bioscience Ltd.; Biolidics Limited; Creativ MicroTech, Inc.; LungLife AI, Inc.; Epic Sciences; Rarecells Diagnostics; ScreenCell; Menarini Silicon Biosystems; LineaRx, Inc. (Vitatex, Inc.); Sysmex Corporation; STEMCELL Technologies, Inc. |
Report Highlights
The CTC detection and enrichment methods segment accounted for the largest revenue share of 75.8%. The availability of different methods for the enrichment of circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period. Moreover, positive or negative enrichment of circulating tumor cells based on biological properties is expected to hold significant potential for market growth.
An effective enrichment process helps in the enhancement of sensitivity, selectivity, and yield, thereby ensuring successful clinical translation of this field. Different detection techniques include magnetic beads-based enrichment, centrifugal force, filtration, and other physical properties such as size, density, deformity, and electric charges.
Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics.
The research segment dominated the market and captured the largest revenue share of 82.8% in 2020. Circulating tumor cells are regarded as a substrate of cancer metastasis. Circulating tumor cells enumeration remains largely a research tool. Recently, the focus has shifted toward circulating tumor cells characterization and isolation, which can provide significant opportunities in predictive testing research.
This arena has significantly improved cancer studies, thus, products offered in the market are primarily designed to be used within research settings. Some key products that have contributed to the large share of research settings are Parsortix Technology, Target Selector Platform, Apostream, Celsee PREP 400, IsoFlux CTC system, DEPArray System, VTX-1, and AdnaTest.
The devices or systems segment dominated the market and accounted for the largest revenue share of 52.8% in 2020. This can be attributed to the presence of a wide portfolio under this category coupled with upcoming advances with regard to microfluidics technology. The introduction of fabricated glass microchips to overcome the challenges and to increase technical completeness for mass production are expected to propel further growth in this segment.
The development of automated instruments that eliminates the use of additional blood collection tubes hampers the revenue growth of blood collection tubes. The reduction in costs is also observed as the transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used.
The blood specimen segment dominated the market and accounted for the largest revenue share of 56.9% in 2020. A large concentration of these cells in blood samples as compared with other biospecimens is responsible for the largest penetration of this specimen type. Approaches for tumor cells identification in blood samples is considered important in current cancer research, as it aids in the prediction of prognosis and determination of the response to systemic chemotherapy. However, the use of whole blood as a specimen poses a challenge when combined with microfluidic technology.
Membrane clogging as a result of a high concentration of blood cells minimizes the applicability of whole blood samples in microfluidic-based circulating tumor cells enumeration. Devices with various pore shapes and sizes are anticipated to overcome this issue and drive segment growth in the coming years. Moreover, the development of fluid-assisted separation technology by Clinomics, a molecular laboratory based in Bloemfontein, Free State can be employed for efficient detection of these cells.
In 2020, North America dominated the Circulating Tumor Cells (CTCs) market and accounted for the largest revenue share of 61.2%. Advanced Cell Diagnostics; Apocell, Inc.; Aviva Biosciences; Biocept, Inc.; Biofluidica, Inc.; and CellTraffix, Inc are the key players operating in the region. These players are undertaking various strategies to enhance their market hold can be attributed to the large share of the U.S. market.
Furthermore, the presence of a population with high susceptibility to cancer, an increase in market penetration rates, and technologically advanced cancer care infrastructure are some of the key factors accounting for its large share. On the other hand, Asia Pacific is projected to grow at a lucrative rate due to high unmet diagnostic needs coupled with rapidly growing patient awareness with regard to early detection of cancer and risk assessment.
Key Players
- QIAGEN
- Bio-Techne Corporation
- Precision for Medicine
- AVIVA Biosciences
- BIOCEPT, Inc.
- BioCEP Ltd.
- Fluxion Biosciences, Inc.
- Greiner Bio One International GmbH
- Ikonisys Inc.
- Miltenyi Biotec
- IVDiagnostics
- BioFluidica
- Canopus Bioscience Ltd.
- Biolidics Limited
- Creativ MicroTech, Inc.
- LungLife AI, Inc.
- Epic Sciences
- Rarecells Diagnostics
- ScreenCell
- Menarini Silicon Biosystems
- LineaRx, Inc. (Vitatex, Inc.)
- Sysmex Corporation
- STEMCELL Technologies, Inc.
Market Segmentation
- Technology Outlook
- CTC Detection & Enrichment Methods
- Immunocapture (Label-based)
- Positive Selection
- Negative Selection
- Size-based Separation (Label-free)
- Membrane-based
- Microfluidic-based
- Density-based Separation (Label-free)
- Combined Methods (Label-free)
- Immunocapture (Label-based)
- CTC Direct Detection Methods
- SERS
- Microscopy
- Others
- CTC Analysis
- CTC Detection & Enrichment Methods
- Application Outlook
- Clinical/ Liquid Biopsy
- Risk Assessment
- Screening and Monitoring
- Research
- Cancer Stem Cell & Tumorogenesis Research
- Drug/Therapy Development
- Clinical/ Liquid Biopsy
- Product Outlook
- Kits & Reagents
- Blood Collection Tubes
- Devices or Systems
- Specimen Outlook
- Blood
- Bone Marrow
- Other Body Fluids
- Regional Outlook
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- UAE
- North America
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/38319
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Circulating Tumor Cells Market, By Technology
7.1. Circulating Tumor Cells Market, by Technology, 2020-2030
7.1.1. CTC Detection & Enrichment Methods
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. CTC Direct Detection Methods
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. CTC Analysis
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Circulating Tumor Cells Market, By Application
8.1. Circulating Tumor Cells Market, by Application, 2020-2030
8.1.1. Clinical/ Liquid Biopsy
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Research
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Circulating Tumor Cells Market, By Product
9.1. Circulating Tumor Cells Market, by Product, 2020-2030
9.1.1. Kits & Reagents
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Blood Collection Tubes
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Devices or Systems
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Circulating Tumor Cells Market, By Specimen
10.1. Circulating Tumor Cells Market, by Specimen, 2020-2030
10.1.1. Blood
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Other Body Fluids
10.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Circulating Tumor Cells Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
Chapter 12. Company Profiles
12.1. QIAGEN
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bio-Techne Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Precision for Medicine
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AVIVA Biosciences
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BIOCEPT, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. BioCEP Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Fluxion Biosciences, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Greiner Bio One International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ikonisys Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Miltenyi Biotec
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. IVDiagnostics
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. BioFluidica
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. Canopus Bioscience Ltd.
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
12.14. Biolidics Limited
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance
12.14.4. Recent Initiatives
12.15. Creativ MicroTech, Inc.
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance
12.15.4. Recent Initiatives
12.16. LungLife AI, Inc.
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance
12.16.4. Recent Initiatives
12.17. Epic Sciences
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance
12.17.4. Recent Initiatives
12.18. Rarecells Diagnostics
12.18.1. Company Overview
12.18.2. Product Offerings
12.18.3. Financial Performance
12.18.4. Recent Initiatives
12.19. ScreenCell
12.19.1. Company Overview
12.19.2. Product Offerings
12.19.3. Financial Performance
12.19.4. Recent Initiatives
12.20. Menarini Silicon Biosystems
12.20.1. Company Overview
12.20.2. Product Offerings
12.20.3. Financial Performance
12.20.4. Recent Initiatives
12.21. LineaRx, Inc. (Vitatex, Inc.)
12.21.1. Company Overview
12.21.2. Product Offerings
12.21.3. Financial Performance
12.21.4. Recent Initiatives
12.22. Sysmex Corporation
12.22.1. Company Overview
12.22.2. Product Offerings
12.22.3. Financial Performance
12.22.4. Recent Initiatives
12.23. STEMCELL Technologies, Inc.
12.23.1. Company Overview
12.23.2. Product Offerings
12.23.3. Financial Performance
12.23.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/38319
About Us: Our team of skilled and experienced analysts specializes in troubleshooting problems faced by our clients. For comprehensive summary of our services and market research requirements for Global industry.
Contact Us:
call: +1 9197 992 333
Vision Research Report
Any Assistance, Email – sales@visionresearchreports.com
